Sanofi-a Ventis Deutschland Gmbh

Ascendis Pharma A/s

Silvia Kaden-Vagt

Harald Rau

Ulrich Hersel

Thomas Wegge

Felix Cleemann

Torben Lessmann

Kennett Sprogoe

Torben Lessman

Kennett Sprogøe

Kennett Sprogoee

Torben LEßMANN

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -Lrepresented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

Prodrugs comprising an insulin linker conjugate

The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.

Long acting insulin composition

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D is insulin; and -Lis: wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

Growing community of inventors

Heidelberg, Germany

Silvia Kaden-Vagt